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ABSTRACT
The incidence of pneumococcal cardiac infections is unknown and the pathogenicity of such
complications is poorly understood. In a prospective, international, observational study, eight of 844
patients hospitalised with Streptococcus pneumoniae bacteraemia developed endocarditis (n = 5) or
pericarditis (n = 3). The clinical and microbiological characteristics of these patients were compared
with those of control patients. The corresponding incidence of pneumococcal endocarditis was c. 1–3 ⁄ 1
million inhabitants ⁄year. There was no common pattern in the medical history of patients with an
infectious cardiac complication. The severity of illness upon admission was comparable with that for
patients without infectious cardiac complications, as was the 14-day mortality rate (25% and 17%,
respectively). For encapsulated S. pneumoniae, no signiﬁcant differences were found between patients
with infectious cardiac complications and controls in adherence assays. However, non-encapsulated
S. pneumoniae showed higher hydrophobicity and increased adherence to human epithelial cells.
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INTRODUCTION
Haematogenous spread of pneumococci may
cause infection in many different locations, inclu-
ding endocarditis and pericarditis [1]. Since peni-
cillin became available, the frequency of
pneumococcal endocarditis has decreased from
10%–15% to <3% [2,3]. However, the true
incidence and factors predisposing to pneumo-
coccal endocarditis have been difﬁcult to estab-
lish. In the pre-antibiotic era, most cases were
discovered at autopsy [4] and, even following the
introduction of penicillin, pneumococcal endocar-
ditis is associated with a very high (24–50%)
mortality rate, with rapid valvular destruction
being the most common cause of death [5–7].
Pericarditis caused by Streptococcus pneumoniae
has been reported less often, with the frequency
of pneumococcal pericarditis found at autopsy of
bacteraemic patients at the John Hopkins Hospital
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(Baltimore, USA) dropping from 51% before 1943
to 9% subsequently, probably because of the
introduction of antibiotics and other therapeutic
advances [8]. Less than 20 cases of pneumococcal
pericarditis have been reported since 1980 [9,10].
Pneumococcal endocarditis and pericarditis
both seem to occur mainly in patients with
concomitant respiratory tract infection [2,8,9,11].
However, little is known concerning the patho-
genesis of these conditions during invasive pneu-
mococcal disease, particularly with respect to the
potential importance of adhesive properties in S.
pneumoniae. The aim of the present study was to
characterise patients who developed endocarditis
or pericarditis during the course of pneumococcal
bacteraemia, in comparison with those who did
not. It was hypothesised that S. pneumoniae
isolates causing such cardiac complications
would have higher adhesive properties than other
isolates.
MATERIALS AND METHODS
Patients and clinical isolates studied
The study focused on eight patients with an infectious
cardiac complication among a cohort of 844 adult patients
with bacteraemic pneumococcal disease. The 844 patients
from 21 hospitals in ten countries were enrolled consecutively
between December 1998 and January 2001 [12]. The eight
patients in the present study came from four of the six
continents represented in the original study [12]: South Africa
(1 ⁄ 248); Spain (2 ⁄ 87); Sweden (2 ⁄ 102); Taiwan (2 ⁄ 46); and the
USA (1 ⁄ 114). Detailed descriptions of the patients have been
published previously [12]. In brief, patients were followed for
‡14 days after the onset of bacteraemia to assess clinical
outcome. Clinical and laboratory data were entered in a
predeﬁned case record form and transferred subsequently
into a central computer database. Most (94%; 793 ⁄ 844) blood
isolates were available for in-vitro susceptibility testing and
serotyping.
For each of the eight patients with an infectious cardiac
complication, one control patient was chosen randomly from
among all patients with no infectious cardiac complications
during the clinical course of bacteraemic pneumococcal dis-
ease. Controls were matched for age (± 5 years) and gender,
but not for geographical location or serotype. Pneumococcal
isolates from patients with endocarditis or pericarditis, and
from controls, were sent to the Swedish Center for Infectious
Disease Control for microbiological analysis. The local ethics
committees at the participating hospitals approved the study.
Bacterial strains and culture conditions
Of the eight isolates studied in detail, ﬁve endocarditis isolates
belonged to serotypes ⁄ serogroups 6, 18 and 19 (one each), and
23 (from two patients), while three pericarditis isolates
belonged to serotypes ⁄ serogroups 7, 14 and 23. The eight
control isolates belonged to serotypes ⁄ serogroups 1, 8, 9, 17, 18
(one isolate each) and 4 (two isolates), and included one
‘rough’ isolate (R8). Additional laboratory strains of S. pneu-
moniae used in the study were T4 (invasive strain TIGR4 [13]),
T4R (non-encapsulated mutant of TIGR4 [14]), D39 (serotype 2;
obtained from P. Herman, Rotterdam, The Netherlands),
R6 (non-encapsulated derivative of D39; obtained from the
Rockefeller University Collection, New York, USA), I95
(invasive clinical isolate of serotype 9V [15]), I95R (non-encap-
sulated variant of I95 [14]), and representative strains of the
oral streptococci Streptococcus mitis and Streptococcus sanguis.
Pneumococci were cultured at 37C on C + Y semisynthetic
medium [16] or on blood agar plates in CO2 5% v ⁄v.
Cell lines
A549 (human type-II alveolar lung epithelium; ATCC CCL-
185), Detroit 562 (human nasopharynx epithelium; ATCC
CCL-138) and PAE (porcine aortic endothelial cell line;
obtained from Y. Cao, MTC, Karolinska Institutet, Stockholm,
Sweden) cell lines were cultured in Ham’s F12K or MEM
medium (Gibco BRL, Rockville, MD, USA) supplemented with
FCS 10% v ⁄v (Gibco BRL) and 5 mM L-glutamine at 37C in
CO2 5% v ⁄v.
Cell-wall hydrocarbon assay
Cell-surface hydrophobicity was measured by adherence of
bacteria to hexadecane as described by Swiatlo et al. [17].
Bacteria were inoculated into C + Y medium at a density of
OD620 0.05 and incubated at 37C for 5 h in F12K medium
(Gibco BRL) supplemented with glucose 1% w ⁄v. After
washing and resuspension in phosphate-buffered saline
(PBS), the OD620 was measured and compared with the
OD620 for the lower aqueous phase after addition and
subsequent separation with hexadecane.
Assessment of biomass production
Bacterial cultures were grown in F12K medium supplemented
with glucose 1% w ⁄v, since glucose has been shown to
improve bioﬁlm formation in oral streptococci [18]. Cultures
were incubated for 4, 8 or 24 h at 37C in CO2 5% v ⁄v in 96-
well plates (Costar 3599; Corning, New York, NY, USA) coated
with collagen I (BD Biosciences, Erembodegem, Belgium) or
ﬁbronectin (Sigma, Poole, UK). The wells were washed, air-
dried, stained with 150 lL crystal violet solution (0.1% w ⁄v),
resuspended in 200 lL of an ethanol-acetone mixture (4 : 1)
and subsequently quantiﬁed at OD590 [19,20]. All experiments
were repeated on three occasions.
Cell adhesion
A549 lung cells, Detroit 562 (data not shown) and PAE cells
were grown to conﬂuence in 96-well plates (Costar 3599) and
incubated with 200 lL F12K medium inoculated with pneu-
mococci (OD620 0.05) for 4 h at 37C in CO2 5% v ⁄v. After ﬁve
washes, the cells were detached from the wells with 50 lL
trypsin (0.25% v ⁄v; 1 mM EDTA) and lysed with 50 lL Triton-
X 0.05% v ⁄v. Bacterial numbers were counted on blood agar
plates following overnight incubation, and the percentage of
adherence was calculated (% adherence = CFU adher-
ence ⁄CFU growth · 100).
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Deﬁnitions
All endocarditis patients were classiﬁed as deﬁnite cases
according to the Duke Criteria [21]. Pericarditis was deﬁned as
the presence of pericardial effusion in an acutely-ill patient
with invasive pneumococcal disease.
Statistics
Data were analysed using GraphPad Instat v.3.05 (GraphPad
Software, San Diego, CA, USA). Categorical data were ana-
lysed using a chi-square or Fisher’s exact test, as appropriate.
Continuous variables were compared using the t-test or the
Mann–Whitney tests. Statistical signiﬁcance was set at p < 0.05.
RESULTS
Patient data
Of the eight (1%) patients with pneumococcal
bacteraemia, ﬁve had endocarditis and three had
pericarditis. All endocarditis patients had vegeta-
tions: two on the aortic, two on the mitral, and one
on both the aortic and themitral valves. Pericardial
drainage was performed in two of the three
patients with pericarditis, and pneumococci were
isolated from the pericardial ﬂuid of one of these.
The mean duration of illness before admission to
hospital was 3.4 (range 2–20) days. An associated
condition was present in all eight patients: pneu-
monia (ﬁve patients); sinusitis (one patient); sinus-
itis plus meningitis (one patient); and septic
arthritis plus meningitis (one patient) (Table 1).
In the case of two patients who had received oral
antibiotics before admission (penicillin V and
doxycycline, respectively), the isolated pneumo-
cocci were fully susceptible to these drugs.
The demographic data, underlying diseases,
severity of illness and clinical course for the eight
patients with endocarditis or pericarditis are
summarised in Table 2, in comparison with the
other 836 patients. Upon admission, the eight
patients had a more marked leukocytosis (white
blood cell count 25.5 · 109 ⁄L vs. 15.5 · 109 ⁄L;
p 0.0168) and were more likely to require treat-
ment in an intensive care unit (75% vs. 19.5%;
p 0.0013) and mechanical ventilation (62.5% vs.
17.2%; p 0.006) than patients without such com-
plications. However, the proportion of patients
who were critically-ill upon admission according
to the Pitt bacteraemia score [12] was similar in
both groups (25% vs. 19.3%). Only one of the
patients with endocarditis required valvular
surgery, and this patient survived. There was a
tendency for concomitant purulent meningitis to
be more common in patients with infectious
cardiac complications (25% vs. 0.6%; p 0.09),
but the 14-day mortality rate was similar for both
groups (25% vs. 17%). Death resulting from
respiratory failure of one of the endocarditis
patients on day 34 increased the total death rate
of those with infectious cardiac complications to
38% (3 ⁄ 8) (Table 1).
Adhesion characteristics of endocarditis and
pericarditis isolates
No signiﬁcant difference in hyrophobicity (1–7%)
was observed between encapsulated endocarditis
isolates and the control strains. However, the
non-encapsulated clinical strain R8 and the non-
encapsulated laboratory strains R6, T4R and I95R,
as well as the oral streptococci, showed a signi-
ﬁcant increase in hydrophobic interaction (30–
50%) with hexadecane. This was especially
marked for R6, T4R and I95R compared with
their isogenic encapsulated counterparts D39, T4
and I95.
Similarly, no signiﬁcant difference was ob-
served between endocarditis and pericarditis
isolates in adherence assays compared with con-
trol strains. S. sanguis, S. mitis and the non-encap-
sulated pneumococcal strains R8, R6, T4R and
I95R showed signiﬁcantly increased adherence to
collagen I in comparison with the encapsulated
strains. Adding soluble collagen I to the medium
during adherence studies prevented adherence to
polyvinylchloride (PVC)- or collagen I-coated
wells. The non-encapsulated strains showed three
to 14-fold increased adherence compared with the
encapsulated clinical and control isolates. The
same adherence pattern was observed in addi-
tional experiments with PVC and ﬁbronectin, and
no differences could be attributed to a speciﬁc
serotype in any of the adherence experiments.
In cell adhesion assays, only non-encapsulated
strains adhered, especially the control strain R8
and the laboratory strain R6, and no signiﬁcant
difference between endocarditis and pericarditis
isolates and control strains was observed.
DISCUSSION
In this prospective, multi-national, study of con-
secutive patients with pneumococcal bacteraemia,
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the frequency of infectious cardiac complications
was 1%. Pneumococcal endocarditis was diag-
nosed in 0.6% (5 ⁄ 844) cases, a slightly lower
frequency than that reported previously (1.2%)
[22]. However, since the present ﬁndings are
based on the largest modern prospective series of
patients with pneumococcal bacteraemia, ob-
tained from many different countries and institu-
tions during a 2-year period, these data may offer
the best current estimate of the risk for pneumo-
coccal endocarditis in a non-selected population.
Assuming an incidence of pneumococcal bacter-
aemia of 20–50 cases ⁄ 100 000 ⁄ year [23], the
corresponding incidence of pneumococcal endo-
carditis would be c. 1–3 ⁄ 1 million inhabit-
ants ⁄ year. In a study among Alaskan natives, a
higher incidence of pneumococcal endocarditis
was found (1.5 ⁄ 100 000 ⁄ year), but this population
is at higher risk for invasive pneumococcal
disease [24].
As in an earlier series [2], pneumonia was the
most common associated condition, and was the
most probable source for bacteraemia and pneu-
mococcal endocarditis. Valvular heart disease and
alcoholism have been reported to be the most
frequent predisposing risk-factors for pneumo-
coccal endocarditis [2,5,6,25,26], but were known
to be present in only one of the eight patients in
the present study. Although human immunode-
ﬁciency virus (HIV) is known to increase the risk
of invasive pneumococcal disease [27,28], its role
in predisposing for endocarditis is not clear [5],
and HIV infection was a frequent underlying
factor in the present study in patients with and
without such complications. Finally, and in agree-
ment with an earlier study [5], 25% of patients
had no known risk-factors for invasive pneumo-
coccal disease.
The small number of patients with endocarditis
or pericarditis in the present study meant that
there was a clear risk for b-errors when the two
groups were compared statistically. However,
with this in mind, no common pattern of under-
lying factors among patients with such complica-
tions was identiﬁed; two were previously healthy,
one had smoking as the only known risk-factor,
while ﬁve had various severe underlying dis-
eases. Intensive care treatment and mechanical
ventilation were needed signiﬁcantly more fre-
quently in patients with infectious cardiac com-
plications, but there was no signiﬁcant difference
in severity upon admission between the two
groups according to the Pitt bacteraemia score,
and both groups had a similar mortality rate. The
14-day mortality rate in patients with pericariditis
was 33% (1 ⁄ 3), and only 20% (1 ⁄ 5) of those with
endocarditis died, which is lower than rates
reported previously [2,5].
The pathogenesis of endocarditis and pericar-
ditis remains a matter of debate. A direct exten-
sion from a pleural empyema may explain some
cases of pneumococcal pericarditis [29], but it is
not known whether there are speciﬁc virulence
attributes, such as capsular types and adhesive
properties, that determine whether a patient will
get an infectious cardiac complication, or whether
host factors are more important. To date, no
speciﬁc bacterial virulence factors have been
Table 2. Demographic data, underlying diseases, severity of illness, and clinical course of adult patients with
pneumococcal bacteraemia (n = 844)
Endocarditis/pericarditis (n = 8) No cardiac complication (n = 836) OR (95%CI) p
Mean age (median) (years) 41.5 (36.5) 52.5 (52) 0.97 (0.94–1.01) NS
Current smoker, n (%) 5 ⁄ 8 (62.5) 345 ⁄ 760a (45.4) 1.4 (0. 8–2.4) NS
Alcoholic, n (%) 1 ⁄ 7b (14.3) 93 (11.2) 1.1 (0.1–9.3) NS
IV drug use, n (%) 1 ⁄ 7b (14.3) 27 (3.3) 4.2 (0.5–35.8) NS
Underlying diseases, n (%)
Rrenal failure 1 (12.5) 61 (7.3) 1.8 (0.2–17.3) NS
HIV 3 (37.5) 214 (25.8) 1.7 (0.3-.8.3) NS
Autoimmune disorder 1 (12.5) 17 (2.0) 6.6 (0.8–48.8) NS
Mean (median) duration of illness before admission, days 3.4 (2.0) 4.4 (3.0) 0.99 (0.95–1.05) NS
White blood cell count, mean (median)c 25.5 (28.8) 15.5 (14.2) 1.04 (1.01–1.08) 0.0168
Penicillin-resistant pneumococci (I + R), n (%) 3d (37.5) 208 (25) 1.8 (0.4–1.6) NS
Pitt bacteramia score (mean)c 3.3 2.7 1.04 (0.92–1.17) NS
Pitt score of 4 + (%)c 25 19.3 1.39 (0.28–6.9) NS
ICU treatment, n (%) 6 (75) 162 (19.5) 12.4 (2.2–89.4) 0. 0013
Mechanical ventilation, n (%) 5 (62.5) 143 (17.2) 8.0 (1.6–42.7) 0.006
Concomitant purulent meningitis, n (%) 2 (25) 55 (0.6) 4.7 (0.9–23.8) 0.09
Mortality at day 14, n (%) 2e (25) 143 (17.2) 1.6 (0.3–8.0) NS
NS, not signiﬁcant; IV, intravenous; HIV, human immunodeﬁciency virus. aStatus unknown in 70 patients. bUnknown in one patient who was unconscious on admission.
cMeasured on admission [12]. A Pitt score of 4+ denotes the most severely-ill patients. dThe serotypes of the three resistant isolates were 6A, 19F and 23F. eThe serotypes of the
two fatal cases were 14 and 23F. In one additional patient (infected by serotype 23), weaning from the mechanical ventilator failed and he was transferred to a respiratory
chronic care unit. This patient died after 5 weeks in hospital.
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shown to be crucial, but streptococci in general
seem to require pre-existing endothelial lesions in
order to adhere to and initiate endocarditis on
cardiac valves [30]. Previous studies observed
that pneumococcal serotypes 12, 1 and 8 are
found most commonly in patients with pneumo-
coccal endocarditis [2], but the eight isolates
investigated in the present study belonged to six
different capsular types, suggesting that any
clonal type may cause an infectious cardiac
complication.
In-vitro assays of adherence and bioﬁlm for-
mation on PVC, polystyrene, collagen I, human
lung, nasopharyngeal or porcine endothelial cells
showed no differences between clinical isolates
causing endocarditis or pericarditis, the control
isolates and the laboratory strains tested, apart
from the effect of the capsule. Thus, there was no
evidence that speciﬁc virulence traits and adher-
ence capabilities were important in causing infec-
tious cardiac complications in pneumococcal
bacteraemia.
A strong correlation was observed between loss
of capsular expression and adherence and poss-
ible bioﬁlm formation. Non-encapsulated strains
showed higher hydrophobicity and an increased
adherence to human epithelial cells, as reported
previously for laboratory strains [17]. The strong
adherence to PVC surfaces in the adherence assay
could indicate possible bioﬁlm formation by S.
pneumoniae. In contrast, the observed adherence
may result solely from the higher hydrophobicity.
The observed adherence also depended on the
growth medium, with greatly increased adher-
ence in minimal medium supplemented with 1%
glucose, as also observed with oral streptococci.
To distinguish pneumococcal bioﬁlm formation
from surface adherence, it will be necessary to
assess the production of extra-polymer matrix or
quorum-sensing interactions. If bioﬁlm formation
occurs in S. pneumoniae, the present results indi-
cate that it may depend on loss or down-regula-
tion of capsular expression, as well as external
factors such as glucose concentration, but not on
other speciﬁc properties of S. pneumoniae.
Colonisation with non-encapsulated S. pneumo-
niae strains is rare [31,32], and little is known about
the regulation of capsular expression during col-
onisation or the amount of capsule produced in
different environments. However, pneumococci of
certain serotypes have been shown to lose capsular
expression when grown in vitro to stationary phase
[14]. Since pneumococci were cultivated only from
blood and not from the heart valve, the possibility
remains that the attached bacteria associated with
endocarditis may be variants with lower capsular
expression than those in blood.
There are several possible limitations to the
present study. First, although the sample size was
small, this is the highest number of infectious
cardiac conditions ever reported in a prospective
study. Since this number was derived from 844
consecutive patients with pneumococcal bacter-
aemia, it is unlikely that a larger sample size will
be available in the foreseeable future. Second, two
distinct clinical entities, endocarditis and pericar-
ditis, were included in the same analysis.
Although these conditions may seem to form a
heterogeneous group, their exact pathogenesis
remains unknown and the adherence ability of S.
pneumoniae may or may not be of importance in
both conditions. Third, only one control per case
was included for the microbiological analysis,
which may limit the power of the ﬁndings.
However, the consistently negative ﬁndings in
the adherence and bioﬁlm formation assays,
except for the non-encapsulated bacterial strains,
indicate that it is unlikely that inclusion of more
controls would have changed the ﬁndings.
Fourth, the diagnosis of pneumococcal pericardi-
tis was only veriﬁed by culture for one of the
three patients. In another patient who was HIV-
positive and had bacteraemic pneumococcal
pneumonia, the pericarditis led to a cardiac
tamponade. When drained, the ﬂuid was puru-
lent, but bacterial cultures were negative. The
third patient, who suffered from systemic lupus
erythematosus (SLE), had no drainage performed
and SLE cannot be ruled out as the cause of the
pericarditis.
In conclusion, an infectious cardiac complica-
tion was a rare event (c. 1% prevalence) among
patients with pneumococcal bacteraemia, and
was not associated with an increased mortality
rate. Patients with such complications had no
common clinical pattern, and the bacterial isolates
causing endocarditis or pericarditis showed no
speciﬁc virulence traits or adherence capabilities.
The association between adherence and capsular
expression in the in-vitro experiments emphasises
the need to study pneumococci that have been
cultivated directly from the valves of endocarditis
patients. Thus, the possibility that host or bacter-
ial factors may be important for the development
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of an infectious cardiac complication cannot be
discounted in the rare event that sufﬁcient
numbers of bacteraemia pneumococci encounter
a heart with a damaged cardiac valve or with
structural damage.
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